Contribute
España
Italia
대한민국
日本
Français
Benzinga
Research
My Stocks
Tools
Free Benzinga Pro Trial
SPY
769.450.1%
QQQ
717.500.2%
BTC/USD
79010.681.6536%
DIA
532.880.22%
GLD
406.530.06%
TLT
82.240.04%

Sangamo Therapeutics Inc

SGMOOTC
Trade with Public
Trade with Public
$0.1776
At close: May 14, 5:00 PM EST
$0.0777
-0.0999-56.25%
After Hours: Jun 23, 9:29 AM EST
OverviewNewsEarnings ForecastEventsPrice TargetsFinancialsSentimentOwnershipCompare

Sangamo Therapeutics Inc Analyst Price Targets

Wall Street analyst price targets and consensus rating for Sangamo Therapeutics Inc (SGMO).

Price Target Range — 10 Quarters

Analyst Consensus — 4 Analysts

3Buy
1Hold
Consensus RatingBuy# Analysts4Avg. Consensus PT$5Upside to Avg. PT+5961.8%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →
DateFirmAnalystActionRating ChangePrice Target
Feb 10, 2026HC Wainwright & Co.Patrick R. TrucchioMaintainedBuy$10
Nov 7, 2025BarclaysGena WangDowngradeOverweight→Equal-Weight$5→$1
More with Benzinga EdgeGet Access

Analyst Ratings News

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

This CarMax Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Friday

Avi Kapoor

PRO
Barclays Downgrades Sangamo Therapeutics to Equal-Weight, Lowers Price Target to $1

Barclays analyst Gena Wang downgrades Sangamo Therapeutics (NASDAQ:SGMO) from Overweight to Equal-Weight and lowers the price target from $5 to $1.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
HC Wainwright & Co. Reiterates Buy on Sangamo Therapeutics, Maintains $10 Price Target

HC Wainwright & Co. analyst Patrick Trucchio reiterates Sangamo Therapeutics (NASDAQ:SGMO) with a Buy and maintains $10 price target.
Benzinga Newsdesk

PRO
Barclays Maintains Overweight on Sangamo Therapeutics, Lowers Price Target to $5

Barclays analyst Gena Wang maintains Sangamo Therapeutics (NASDAQ:SGMO) with a Overweight and lowers the price target from $9 to $5.
Benzinga Newsdesk

Data & APIs: Benzinga APIs · Stock News API · Analyst Ratings API · Company Logo API

Market data provided by Benzinga APIs

Connect With Us
instagramlinkedinyoutubeblueskymastodon
About Benzinga
Market Resources
Trading Tools & Education
Ring the Bell
© 2026 Benzinga | All Rights Reserved